Virus therapy joins Chemo-Radiation in fight against rectal cancer

NCT ID NCT06459869

Recruiting now Disease control Sponsor: Akamis Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of the tumor disappearing completely before surgery. About 30 adults with a specific type of rectal cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NG-350A (a virus that delivers an immune-stimulating protein to tumors), capecitabine (chemotherapy), and radiotherapy
What this could lead to: If it works, this could point toward a more effective treatment for locally advanced rectal cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong: This is an early phase 1 trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects, and the virus-based therapy might not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CANCER (LARC)

Contacts and locations

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32804, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
The Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, United Kingdom
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University College London NHS FT
RECRUITING

London, United Kingdom
University of Southern California
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90033, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.